| Literature DB >> 34917023 |
Vincenza Granata1, Francesca Coppola2, Roberta Grassi3,4, Roberta Fusco5, Salvatore Tafuto6, Francesco Izzo7, Alfonso Reginelli4, Nicola Maggialetti8, Duccio Buccicardi9, Barbara Frittoli10, Marco Rengo11, Chandra Bortolotto12, Roberto Prost13, Giorgia Viola Lacasella4, Marco Montella4, Eleonora Ciaghi14, Francesco Bellifemine14, Federica De Muzio15, Ginevra Danti16, Giulia Grazzini16, Massimo De Filippo17, Salvatore Cappabianca4, Carmelo Barresi18, Franco Iafrate19, Luca Pio Stoppino20, Andrea Laghi21, Roberto Grassi3,4, Luca Brunese15, Emanuele Neri3,22, Vittorio Miele3,16, Lorenzo Faggioni22.
Abstract
Background: Structured reporting (SR) in radiology is becoming increasingly necessary and has been recognized recently by major scientific societies. This study aims to build structured CT-based reports in Neuroendocrine Neoplasms during the staging phase in order to improve communication between the radiologist and members of multidisciplinary teams. Materials andEntities:
Keywords: computed tomography; neuroendocrine neoplasm; radiology report; staging; structured report
Mesh:
Year: 2021 PMID: 34917023 PMCID: PMC8670531 DOI: 10.3389/fendo.2021.748944
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Single scores and sum of scores of 14 panellists for the structured report in the first round.
| Panellist # | A1. Anthropometric data | A2. Personal assessments | A3. Allergies and adverse reactions | B1. Clinical information | C1. Exam data | C2. Contrast agent | C4. Adverse Events | D1. Lesion | D2. Lymphadenopathy | D3. Distantmetastasis | D8. Accessoryfindings | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 54 |
| 2 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 54 |
| 3 | 3 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 51 |
| 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 51 |
| 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 6 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 54 |
| 7 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 8 | 4 | 4 | 5 | 4 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 51 |
| 9 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 1 | 51 |
| 10 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 53 |
| 11 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 54 |
| 12 | 3 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 3 | 3 | 48 |
| 13 | 5 | 3 | 4 | 5 | 3 | 5 | 4 | 3 | 5 | 3 | 5 | 45 |
| 14 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 52 |
| Mean | 4.43 | 4.21 | 4.86 | 4.93 | 4.79 | 5.00 | 4.93 | 4.79 | 5.00 | 4.71 | 4.36 | 52.00 |
| Std | 0.73 | 0.67 | 0.35 | 0.26 | 0.56 | 0.00 | 0.26 | 0.56 | 0.00 | 0.70 | 1.11 | 2.83 |
Single scores and sum of scores of 14 panellists for the structured report in the second round.
| Panellist # | A1. Anthropometric data | A2. Personal assessments | A3. Allergies and adverse reactions | B1. Clinical information | C1. Exam data | C2. Contrast agent | C4. Adverse Events | D1. Lesion | D2. Lymphadenopathy | D3. Distant metastasis | D8. Accessory findings | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 2 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 54 |
| 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 7 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 51 |
| 8 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 9 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 10 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 11 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 12 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 50 |
| 13 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| 14 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 55 |
| Mean | 4.93 | 4.86 | 4.86 | 5.00 | 4.93 | 4.93 | 4.93 | 5.00 | 5.00 | 5.00 | 4.86 | 54.29 |
| Std | 0.27 | 0.36 | 0.36 | 0.00 | 0.27 | 0.27 | 0.27 | 0.00 | 0.00 | 0.00 | 0.36 | 1.64 |